baloxavir marboxil wikipedia - EAS
See more
See all on Wikipediahttps://en.wikipedia.org/wiki/Baloxavir_marboxilBaloxavir marboxil (BXM), sold under the brand name Xofluza, is an antiviral medication for treatment of influenza A and influenza B flu. It was approved for medical use both in Japan and in the United States in 2018, and is taken as a single dose by mouth. It may reduce the duration of flu
...
See moreBaloxavir marboxil is an influenza medication, an antiviral, for individuals who are twelve years of age or older, that have presented symptoms of this infection for no more than 48 hours. The efficacy of baloxavir marboxil
...
See moreCommon side effects following the single dose administration of baloxavir marboxil include diarrhea, bronchitis, common cold, headache, and nausea. Adverse events were reported in 21% of
...
See moreBaloxavir marboxil is a substituted pyridone derivative of a polycyclic family, whose chemical synthesis has been reported in a number of ways by the company discovering it, Shionogi and Co. of Japan (as well as others); the Shionogi reports have appeared
...
See more
Baloxavir marboxil should not be co-administered with dairy products, calcium-fortified beverages, or laxatives, antacids, or oral supplements containing calcium, iron, magnesium, selenium, aluminum or zinc.
...
See moreBaloxavir marboxil is an influenza therapeutic agent, specifically, an enzyme inhibitor targeting the influenza virus' cap-dependent endonuclease activity, one of the activities of the virus polymerase complex. In particular, it inhibits a process known as
...
See moreBXM was developed for the market by Shionogi Co., a Japanese pharmaceutical company, and Switzerland-based Roche AG. The names under which BXM and BXA appear in Shionogi
...
See moreWikipedia text under CC-BY-SA license- https://es.wikipedia.org/wiki/Baloxavir_Marboxil
Baloxavir marboxil, originalmente S-033188, es un fármaco antiviral desarrollado por la compañía Shionogi, un laboratorio farmacéutico Japonés con base en Osaka.
El fármaco fue puesto a consideración del Ministerio de Salud, Trabajo y Bienestar de Japón el 25 de octubre de 2017 y aprobado en Japón en febrero d…Wikipedia · Text under CC-BY-SA license - People also ask
- https://en.wikipedia.org/wiki/File:Baloxavir_marboxil.svg
Original file (SVG file, nominally 1,410 × 1,240 pixels, file size: 39 KB)
- https://en.wikipedia.org/wiki/Talk:Baloxavir_marboxil
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles.Here are links to possibly useful sources of information about Baloxavir marboxil.. PubMed provides review articles from the past five years (limit to free review articles); The TRIP database provides clinical publications about …
- (Rated Start-class, High-importance): WikiProject …
- https://wikem.org/wiki/Baloxavir_marboxilSee more on wikem.org
- Type: Antiviral
- Dosage Forms: 20 mg, 40 mg tab
- Routes of Administration: PO
- Common Trade Names: Xofluza
- https://nn.wikipedia.org/wiki/Baloxavir_marboxil
Baloxavir marboxil er ei lita kjemisk sambinding og ein endonukleasehemjar. Ho er per september 2018 under utrøyning som lækjemiddel mot influensavirus og har vist lovande resultat. Ho verkar gjennom å hemja endonukleasen nytta av influensaviruset når det skal mangfalda seg.
- https://www.wikipedia.org/wiki/Baloxavir-marboxil
Moved Permanently. The document has moved here.
- https://pubchem.ncbi.nlm.nih.gov/compound/Baloxavir-marboxil
Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease which prevents polymerase function and therefore influenza virus mRNA replication,. It has shown therapeutic activity against influenza A and B virus infections, including strains resistant to current antiviral agents.
- https://en.wikipedia.org/wiki/Oseltamivir
Oseltamivir, sold under the brand name Tamiflu, is an antiviral medication used to treat and prevent influenza A and influenza B, the viruses that cause the flu. Many medical organizations recommend it in people who have complications or are at high risk of complications within 48 hours of first symptoms of infection. They recommend it to prevent infection in those at high …
- Some results have been removed
